Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder

American Journal of Psychiatry

Volumn 161, Issue 6, 2004, Pages 975-984

  Meltzer, Herbert Y ^b   Arvanitis, Lisa ^a   Bauer, Deborah ^b   Rein, Werner ^b  

^a Sanofi Research Division   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 [[1 (7 CHLORO 4 QUINOLINYL) 5 (2,6 DIMETHOXYPHENYL) 3 PYRAZOLYL]CARBONYLAMINO] 2 ADAMANTANECARBOXYLIC ACID; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; ALTANSERIN; AMISULPRIDE; BENZATROPINE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CHLORAL HYDRATE; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; EPLIVANSERIN; FLUORINE 18; HALOPERIDOL; LORAZEPAM; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NEUROKININ 3 RECEPTOR; NEUROKININ 3 RECEPTOR ANTAGONIST; NEUROLEPTIC AGENT; NEUROTENSIN RECEPTOR ANTAGONIST; OLANZAPINE; OSANETANT; PLACEBO; RIMONABANT; RISPERIDONE; SEROTONIN 1A ANTAGONIST; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2C ANTAGONIST; UNINDEXED DRUG;

ADULT; AGITATION; AKATHISIA; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEADACHE; HUMAN; HYPERKINESIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE HYPERTONIA; OUTCOMES RESEARCH; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCORING SYSTEM; SIDE EFFECT; TREMOR; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; CANNABINOIDS; DOUBLE-BLIND METHOD; DRUGS, INVESTIGATIONAL; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; NEUROTENSIN; PEPTIDE FRAGMENTS; PIPERIDINES; PLACEBOS; PSYCHOTIC DISORDERS; PYRAZOLES; PYRROLIDONECARBOXYLIC ACID; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, NEUROKININ-3; RESEARCH DESIGN; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 2942538034     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.161.6.975     Document Type: Article

References (52)

1. Meltzer HY: Mechanism of action of atypical antipsychotic drugs, in Neuropsychopharmacology: The Fifth Generation of Progress. Edited by Davis KL, Charney D, Coyle JT, Nemeroff C. Philadelphia, Lippincott Williams & Wilkins, 2002, pp 819-832
2. Barnes TR, McPhillips MA: Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics. Br J Psychiatry Suppl 1999; 38:34-43
3. Harvey PD, Keefe RSE: Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 2001; 158:176-184
4. Duncan GE, Zorn S, Lieberman JA: Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia. Mol Psychiatry 1999; 4:418-428
5. Marcotte ER, Pearson DM, Srivastava LK: Animal models of schizophrenia: a critical review. J Psychiatry Neurosci 2001; 26: 395-410
6. 3 receptor expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther 1995; 274:148-154
7. 3 receptor stimulation in gerbil mesencephalic cell cultures. Eur J Neurosci 1996; 8:801-808
8. 3 receptor. Life Sci 1995; 56:PL27-PL32
9. 3 receptor. Pharmacology 1996; 52:283-291
10. 3 receptor stimulation. Neuroscience 1996; 74:403-414
11. 3 receptor stimulation: an in vivo microdialysis approach in guinea pig. Neuropeptides 1998; 32:481-488
12. Gueudet C, Santucci V, Soubriè P, Le Fur G: Blockade of neurokinin-3 receptors antagonizes drug-induced population response and depolarization block of midbrain dopamine neurons in guinea pigs. Synapse 1999; 33:71-79
13. Rinaldi-Carmona M, Congy C, Santucci V, Simiand J, Gautret B, Neliat G, Labeeuw B, Le Fur G, Soubriè P, Brelier JC: Biochemical and pharmacological properties of SR46349B, a new potent and selective 5-hydroxytryptamine 2 receptor antagonist. J Pharmacol Exp Ther 1992; 262:759-768
14. Rinaldi-Carmona M, Congy C, Simiand J, Oury-Donat F, Soubriè P, Brelière JC, Le Fur G: Repeated administration of SR 46349B, a selective 5-hydroxytryptamine2 antagonist, up-regulates 5-hydroxytryptamine2 receptors in mouse brain. Mol Pharmacol 1993; 43:84-89
15. 2 receptor antagonist. Eur J Pharmacol 1993; 246:73-80
16. Millan MJ, Brocco M, Gobert A, Joly F, Bervoets K, Rivet J, Newman-Tancredi A, Audinot V, Maurel S: Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5-HT2A sites for PCP-induced locomotion in the rat. Eur J Neurosci 1999; 11:4419-4432
17. 2A/2C receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology 2002; 27:430-441
18. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G, Caput D, Ferrara P, Soubriè P, Brelière JC, Le Fur G: SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994; 350:240-244
19. Collins DR, Pertwee RG, Davies SN: Prevention by the cannabinoid antagonist, SR141716A, of cannabinoid-mediated blockade of long-term potentiation in the rat hippocampal slice. Br J Pharmacol 1995; 115:869-870
20. Poncelet M, Barnouin MC, Brelière JC, Le Fur G, Soubriè P: Blockade of cannabinoid (CB1) receptors by SR141716 selectively antagonizes drug-induced reinstatement of exploratory behavior in gerbils. Psychopharmacology (Berl) 1999; 144: 144-150
21. Alonso R, Voustsinos B, Fournier M, Labie C, Steinberg R, Souilhac J, Le Fur G, Soubriè P: Blockade of (CB1) cannabinoid receptors by SR141716 selectively increases Fos expression in rat mesocorticolimbic areas via reduced dopamine D2 function. Neuroscience 1999; 91:607-620
22. Hermans E, Octave JN, Maloteaux JM: Receptor mediated internalization of neurotensin in transfected Chinese hamster ovary cells. Biochem Pharmacol 1994; 47:89-91
23. Oury-Donat F, Thurneyssen O, Gonalons N, Forgez P, Gully D, Le Fur G, Soubriè P: Characterization of the effect of SR48692 on the intracellular events linked to neurotensin receptor activation. Br J Pharmacol 1995; 116:1899-1905
24. Steinberg R, Brun P, Fournier M, Souilhac J, Rodier D, Mons G, Terranova JP, Le Fur F, Soubriè P: SR 48692, a non-peptide neurotensin receptor antagonist, differentially affects neurotensin-induced behaviour and changes in dopaminergic transmission. Neuroscience 1994; 59:921-929
25. Azzi M, Nicot A, Gully D, Kitabgi P, Berod A, Rostène W: Increase in neurotensin receptor expression in rat brain induced by chronic treatment with the nonpeptide neurotensin receptor antagonist SR48692. Neurosci Lett 1994; 172:97-100
26. 3H]dopamine release in rat striatal slices and mesencephalic cultures. Eur J Pharmacol 1994; 253:289-291
27. Poncelet M, Souilhac J, Gueudet C, Terranova JP, Gully D, Le Fur G, Soubriè P: Effect of SR48692, a selective non-peptide neurotensin receptor antagonist, on two dopamine-dependent behavioral responses in mice and rats. Psychopharmacology (Berl) 1994; 116:237-241
28. Michaud JC, Gueudet C, Soubriè P: Effects of neurotensin receptor antagonists on the firing rate of rat ventral pallidum neurons. Neuroreport 2000; 11:1437-1441
29. Alonso R, Gnanadicom H, Frechin N, Fournier M Le Fur G, Soubriè P: Blockade of neurotensin receptors suppresses the dopamine D1/D2 synergism on immediate early gene expression in the rat brain. Eur] Neurosci 1999; 11:967-974
30. Scatton B, Sanger DJ: Pharmacological and molecular targets in the search for novel antipsychotics. Behav Pharmacol 2000; 11:243-256
31. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261-276
32. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976, pp 218-222
33. Addington D, Addington J, Schissel B: A depression rating scale for schizophrenics. Schizophr Res 1990; 3:247-251
34. Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11-19
35. Barnes TRE: A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154:672-676
36. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976, pp 534-537
37. Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10:799-812
38. Janicak PG, Davis JM: Antipsychotic dosing strategies in acute schizophrenia. Int Clin Psychopharmacol 1996; 11(suppl 2):35-40
39. Zhang-Wong J, Zipursky RB, Beiser M, Bean G: Optimal haloperidol dosage in first-episode psychosis. Can J Psychiatry 1999; 44:164-167
40. McGorry PD: Recommended haloperidol and risperidone doses in first-episode psychosis. J Clin Psychiatry 1999; 60:794-795
41. 7) receptors. J Pharmacol Exp Ther 1994; 268:1406-1410
42. Moghaddam B, Bunney BS: Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J Neurochem 1990; 54:1755-1760
43. Li XM, Perry KW, Wong DT, Bymaster FP: Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology (Berl) 1998; 136:153-161
44. Kuroki T, Meltzer HY, Ichikawa J: Effect of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 1999; 288: 774-781
45. Meltzer HY, McGurk SR: The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999; 25:233-255
46. 1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 2001; 76:1521-1531
47. Potkin SG, Shipley J, Bera RB, Carreon D, Fallon J, Alva G, Keator D: Clinical and PET effects of M100905, a selective 5HT-2A receptor antagonist (abstract). Schizophr Res 2001; 49(1, suppl 2):242
48. Dean B, Sundram S, Bradbury R, Scarr E, Copolov D: Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 2001; 103:9-15
49. Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D: Elevated endogenous cannabinoids in schizophrenia. Neuroreport 1999; 10:1665-1669
50. Kupfer DJ, Detre T, Koral J, Fajans P: A comment on the "amotivational syndrome" in marijuana smokers. Am J Psychiatry 1973; 130:1319-1322
51. Binder EB, Kinkead B, Owens MJ, Kilts CD, Nemeroff CB: Enhanced neurotensin neurotransmission is involved in the clinically relevant behavioral effects of antipsychotic drugs: evidence from animal models of sensorimotor gating. J Neurosci 2001; 21:601-608
52. Binder EB, Kinkead B, Owens MJ, Nemeroff CB: The role of neurotensin in the pathophysiology of schizophrenia and the mechanism of action of antipsychotic drugs. Biol Psychiatry 2001; 50:856-887